Vascular endothelial cell growth factor variants and uses...

Details Vascular endothelial cell growth factor variants and uses... Vascular endothelial cell growth factor variants and uses...

2006-08-15

2006-08-15

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C435S007100, C435S007200, C435S069100, C435S069400, C435S325000, C435S252300, C435S254110, C435S320100, C530S399000, C436S501000, C536S023500, C536S023510, C930S120000

Reexamination Certificate

active

07090834

ABSTRACT:
The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

REFERENCES:
patent: 6020473 (2000-02-01), Keyt et al.
patent: 2002/0169292 (2002-11-01), Weintraub et al.
patent: WO 90/13649 (1990-11-01), None
patent: WO 97/08313 (1997-03-01), None
patent: WO 98/16551 (1998-04-01), None
Y.A.-Muller et al., “VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface” Structure 6:1153-1167, Sep. 15, 1998.
G. Siemeister et al., “The α-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor”, J. Biol. Chem. 273(18):11115-11120, May 1, 1998.
Burgess and Maciag, “The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins”Annu. Rev. Biochem.58:575-606 (1989).
Cao et al., “Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR”Journal of Biological Chemistry271(6):3154-3162 (Feb. 9, 1996).
Cunningham et al., “Interactions of FLT-1 and KDR with phospholipase C γ: Identification of the phosphotyrosine binding sites”Biochemical&Biophysical Research Communications240(3):635-639 (Nov. 26, 1997).
Dougher and Terman, “Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and reception internalization”Oncogene18(8):1619-1627 (Feb. 25, 1999).
Ferrara et al., “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells”Biochem.&Biophys. Res. Comm.161(2):851-858 (Jun. 15, 1989).
Ferrara et al., “The biology of vascular endothelial growth factor”Endocrine Reviews18(1):4-25 (Feb. 1997).
Ferrara, N., “Vascular endothelial growth factor. The trigger for neovascularization in the eye”Laboratory Investigation72(6):615-618 (1995).
Fuh et al., “Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor”Journal of Biological Chemistry273(18):11197-11204 (May 1, 1998).
Gerber et al., “Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation”Journal of Biological Chemistry273(46):30336-30343 (Nov. 13, 1998).
Ishikawa et al., “Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor”Nature338:357-362 (1989).
Ito et al., “Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules”Journal of Biological Chemistry273(36):23410-23418 (Sep. 4, 1998).
Jin et al., “Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats”Journal of Clinical Investigation98(4):969-976 (Aug. 15, 1996).
Keyt et al., “Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors: Generation of receptor-selective VEGF variants by site-directed mutagenesis”Journal of Biological Chemistry271(10):5638-5646 (1996).
Keyt et al., “The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency”Journal of Biological Chemistry271(13):7788-7795 (Mar. 29, 1996).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology204:125-139 (1991).
Landgren et al., “Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1”Oncogene16(3):359-367 (Jan. 22, 1998).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”Science246:1306-1309 (Dec. 1989).
Maglione et al., “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor”Proc. Natl. Acad. Sci.88:9267-9271 (1991).
Malavaud et al., “Activation of Flk-1/KDR mediates angiogenesis but not hypotension ”Cardiovascular Research36(2):276-281 (Nov. 1997).
Marte and Downward, “PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond”Trends in Biochemical Sciences22(9):355-358 (Sep. 1997).
Meyer et al., “A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases”EMBO Journal18(2):363-374 (Jan. 15, 1999).
Muller et al., “The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding”Structure5(10):1325-1338 (Oct. 15, 1997).
Muller et al., “Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site”Proc. Natl. Acad. Sci. USA94(14):7192-7197 (Jul. 8, 1997).
Muller et al., “VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface”Structure6(9):1153-1167 (Sep. 15, 1998).
Ogawa et al., “A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain”Journal of Biological Chemistry273(47):31273-31282 (Nov. 20, 1998).
Olofsson et al., “Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells”Proc. Natl. Acad. Sci. USA95(20):11709-11714 (Sep. 29, 1998).
Park et al., “Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR”Journal of Biological Chemistry269(41):25646-15654 (1994).
Polverini et al., “Assay and purification of naturally occurring inhibitor of angiogenesis”Methods in Enzymology198:440-450 (1991).
Rousseau et al., “p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells”Oncogene15(18):2169-2177 (Oct. 1997).
Sawano et al., “Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor”Cell Growth&Differentiation7(2):213-221 (Feb. 1996).
Sawano et al., “The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCγ”Biochemical&Biophysical Research Communications238(2):487-491 (Sep. 18, 1997).
Seetharam et al., “A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF”Oncogene10(1):135-147 (Jan. 5, 1995).
Tischer et al., “Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family”Biochem.&Biophys. Res. Comm.165:1198-1206 (1989).
Waltenberger et al., “Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor”Journal of Biological Chemistry269(43):26988-26995 (Oct. 28, 1994).
Walter et al., “The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independant of N-linked glycosylation”Laboratory Investigation74

Affiliated with

Also associated with

Rating

Vascular endothelial cell growth factor variants and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial cell growth factor variants and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial cell growth factor variants and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3619687